false 0000898437 0000898437 2024-02-24 2024-02-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 24, 2024

 

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-14027 04-3145961
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

32 Wiggins Avenue

Bedford, Massachusetts 01730

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (781) 457-9000

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share ANIK NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 24, 2024, Jeffery S. Thompson notified Anika Therapeutics, Inc. (the “Company”) of his intention to retire from the Board of Directors (the “Board”) after 13 years of dedicated service at the end of his current term. Mr. Thompson’s retirement will be effective as of the Company’s 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Following Mr. Thompson’s retirement, the Board will be comprised of seven directors, and two Class I directors will be elected at the Annual Meeting.

 

Mr. Thompson’s decision is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.

 

In connection with Mr. Thompson’s planned retirement, John B. Henneman, III, an independent director of the Company’s Board since 2020, has been appointed Chair of the Board, effective immediately.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  Anika Therapeutics, Inc.
     
     
Date: February 26, 2024 By:   /s/ Cheryl R. Blanchard
    Cheryl R. Blanchard
    President and Chief Executive Officer
     

 

 

 

 

v3.24.0.1
Cover
Feb. 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 24, 2024
Entity File Number 001-14027
Entity Registrant Name Anika Therapeutics, Inc.
Entity Central Index Key 0000898437
Entity Tax Identification Number 04-3145961
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 32 Wiggins Avenue
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 457-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ANIK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Anika Therapeutics Charts.
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Anika Therapeutics Charts.